Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp, a wholly owned subsidiary of Cencora, Inc., operates as a full-and-open pharmaceutical wholesaler and medical distributor supplying brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices to the Department of Defense and federal healthcare systems as a prime contractor. The company competes without set-aside restrictions and holds no SBA certifications. Amerisourcebergen is headquartered in Conshohocken, Pennsylvania, and operates under NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers) and PSC code 6515.

The company's federal footprint is dominated by transactional pharmaceutical delivery orders under Defense Logistics Agency indefinite delivery contracts. Over 5.2 million prime awards spanning more than three decades carry a combined potential value of $1.49 trillion, with customer concentration singularly focused on DLA. The top two customer entities — DLA Troop Support Medical (3,799,505 awards, $535.32 billion combined potential value) and the Defense Logistics Agency proper (1,416,690 awards, $898.68 billion combined potential value) — account for 100% of recent award volume and 96% of combined potential value. A distant third customer is the Department of Health and Human Services National Institutes of Health Office of the Chief Operating Officer (4,537 awards, $237.4 million), followed by the Department of Veterans Affairs and HHS's Office of the Assistant Secretary for Preparedness and Response. The vendor serves 35 distinct customer agencies in total, but DLA's Troop Support Medical segment represents the overwhelming operating reality.

Amerisourcebergen's transactional footprint consists almost entirely of firm fixed-price delivery orders ranging from under one hundred dollars to several million dollars per order. Representative recent awards include a $321,264 purchase order from Veterans Integrated Service Network 7 for drospirenone tablets (July 17, 2026), a $1.79 million delivery order from DLA Medical Supply Chain for pharmaceutical branch supply (July 17, 2026), and a $456,749.70 delivery order from DLA Medical Supply Chain (July 17, 2026). Other named recent orders span specialty injectables including Dupixent, Mounjaro, Ozempic, Zepbound, Humira, Cosentyx, and Kesimpta, as well as vaccines (Gardasil 9, Shingrix, M-M-R II), controlled substances, and standard pharmaceuticals ranging across cardiology, neurology, oncology, psychiatry, and infectious disease therapeutic domains.

The vendor holds a single-award indefinite delivery contract (SPE2DX, awarded June 10, 2026) with the Defense Logistics Agency's Troop Support Medical division, valued at $4.999 million through December 31, 2036, supporting the Pharmaceutical Prime Vendor Global Program Generation V for worldwide military healthcare supply. Five named parent indefinite delivery contract vehicles dominate activity: SPE2DX22D0019 (66,462 task orders, $1.77 billion combined potential value), SPE2DX15D1022 (77,047 task orders, $993.3 million), SPE2DX15D2206 (69,342 task orders, $908.8 million), SPE2DX15D1053 (82,481 task orders, $784 million), and SPE2DX15D1106 (67,841 task orders, $422.8 million). These vehicles represent standing pharmaceutical supply channels through which Amerisourcebergen executes high-volume transactional orders to military treatment facilities, Defense Health Agency components, and VA facilities globally.

Award volume has remained stable year over year across the past five years (approximately 300,000–500,000 awards annually from 2022 through 2026), though the data reflects the extraordinary scale of DLA pharmaceutical distribution — the top 5.2 million award count includes millions of individual line-item orders, many sub-$1,000, aggregating to $63.96 billion in obligated dollars across the $1.49 trillion potential-value ceiling. Recompete exposure in the next twenty-four months is negligible (only one award, $28 thousand, reaching ultimate completion). The vendor's customer concentration, award volume, and vehicle positioning signal a mission-critical role in military pharmaceutical supply, anchored to DLA Troop Support Medical's indefinite delivery structure rather than full-and-open competition across multiple agencies.